CLINICAL_TRIALS
trial_result
· 2023-06-05
Clinical Trial Update: Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis [Phase 2]
Summary
Phase 2 trial update on belumosudil for diffuse cutaneous systemic sclerosis; study terminated with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Kadmon, a Sanofi Company | Conditions: Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2023-06-05